About Manifold Bio
Manifold Bio is a company based in United States founded in 2018 by Gleb Kuznetsov, Shane Lofgren, Pierce Ogden, and George M Church. Manifold Bio has raised $78.19 million across 3 funding rounds from investors including Tencent, Triatomic Capital and Future Perfect Ventures. The company has 22 employees as of December 31, 2022. Manifold Bio offers products and services including Tissue-Targeted Biologics and mCodes Technology.
- Headquarter United States
- Employees 22 as on 31 Dec, 2022
- Founders Gleb Kuznetsov, Shane Lofgren, Pierce Ogden, George M Church
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Manifold Bio, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78.19 M (USD)
in 3 rounds
-
Latest Funding Round
$32.78 M (USD), Series A
Nov 18, 2024
-
Investors
Tencent
& 8 more
-
Employee Count
22
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Manifold Bio
Manifold Bio offers a comprehensive portfolio of products and services, including Tissue-Targeted Biologics and mCodes Technology.
Targeted biologics are developed using high-throughput in vivo screening and AI to optimize pharmacokinetics and biodistribution for tissue-specific delivery
mCodes technology is utilized as multiplexed protein barcodes for tracking and measuring biologics across tissues with high sensitivity
People of Manifold Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Manifold Bio
Manifold Bio has successfully raised a total of $78.19M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $32.78 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Manifold Bio
Manifold Bio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Triatomic Capital and Future Perfect Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Triatomic Capital is focused on investing in century-defining technological themes.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on blockchain technology sectors
|
Locked | Locked | Locked | |
|
Horizons Ventures is focused on investing in deep science and technology.
|
Locked | Locked | Locked |
Investor details for Manifold Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Manifold Bio
Investment portfolio details for Manifold Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Manifold Bio
Detailed financials for Manifold Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Manifold Bio Comparisons
Peer comparison for Manifold Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Manifold Bio
Detailed competitors of Manifold Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Manifold Bio
Complete news archive for Manifold Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Manifold Bio
Manifold Bio was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Manifold Bio is headquartered in United States.
Gleb Kuznetsov is the current CEO of Manifold Bio. They have also founded this company.
Manifold Bio is a funded company, having raised a total of $78.19M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Manifold Bio is 22.
Manifold Bio was founded in 2018 and is based in the United States. Operations focus on the biotechnology sector, where pharmacological assessments of therapeutic protein variants are performed. The lab supports drug development through precise measurements and analysis. Key leadership includes co-founders Gleb Kuznetsov as CEO, Shane Lofgren, Pierce Ogden as CSO, and George M. Church. Research activities are centered on advancing protein-based therapeutics.
Manifold Bio offers Tissue-Targeted Biologics and mCodes Technology.
Manifold Bio has 9 investors. Key investors include Tencent, Triatomic Capital, Future Perfect Ventures, Horizons Ventures, and Fifty Years.